Financial Information
This section houses up-to-date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Sera Prognostics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQSERA
| Beta | 0.27 |
|---|---|
| Shares Outstanding | 31.0M |
| Average Volume (10 days) | 85.4K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 4 | |
|---|---|---|
| Buy | 0 | |
| Hold | 1 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Gregory C. Critchfield Director, Chief Executive Officer | 62,200 Acquire Mar 7, 2023 |
|---|---|
Michael R. Foley Chief Medical Officer | 27,000 Acquire Mar 6, 2023 |
Paul Kearney Chief Data Officer | 16,000 Acquire Mar 6, 2023 |
Benjamin Jackson General Counsel | 24,700 Acquire Mar 6, 2023 |
Robert G. Harrison Chief Information Officer | 28,500 Acquire Mar 6, 2023 |
Email Alerts
Sign up for our investor relations email list here.